Pharma Distribution 13Fs: McKesson, Cencora, Cardinal Health

US-traded pharmaceutical distribution equities form a distinctive healthcare services corner of institutional 13F positioning. McKesson (MCK, largest US pharma distributor), Cencora (COR, formerly AmerisourceBergen, rebranded August 2023), Cardinal Health (CAH), Henry Schein (HSIC, see dental supplies decoder), plus Owens & Minor (OMI, medical-surgical distribution plus emerging emerging Patient Direct home delivery) anchor the cohort. Multi-year emerging specialty pharma growth, GLP-1 distribution dynamics, plus emerging emerging opioid settlement payments drive distinctive institutional positioning. Reading pharma distribution 13F positioning requires understanding the distribution-vs-services framework plus the multi-year dynamics.

The pharma distribution business model

Pharma distribution companies operate four primary economic engines:

1. Distribution economics. Multi-year emerging distribution economics drives operator revenue. Multi-year emerging brand-name plus emerging emerging generic plus emerging emerging specialty plus emerging emerging biosimilar distribution drives multi-year emerging emerging operator economics. Multi-year emerging emerging Big 3 (McKesson, Cencora, Cardinal Health) 90%+ US pharma distribution market share plus emerging emerging emerging emerging operator oligopoly drives multi-year emerging pricing power.
2. Specialty pharma growth. Multi-year emerging specialty pharma growth drives operator economics. Multi-year emerging specialty pharma (oncology, autoimmune, rare disease, ophthalmology, plus emerging emerging emerging emerging others) growing 8-12% annually plus emerging emerging emerging emerging higher gross margin than brand plus emerging emerging emerging emerging Limited Distribution Network (LDN) plus emerging emerging specialty pharmacy plus emerging emerging Direct-to-Patient drive multi-year emerging emerging operator economics.
3. GLP-1 distribution dynamics. Multi-year emerging GLP-1 distribution dynamics drives multi-year emerging operator economics. Multi-year emerging Eli Lilly Mounjaro-Zepbound plus emerging emerging Novo Nordisk Ozempic-Wegovy distribution through Big 3 drives multi-year emerging emerging operator revenue scaling plus emerging emerging emerging emerging supply-demand-driven volatility plus emerging emerging emerging emerging emerging emerging operator pricing dynamics. Multi-year emerging emerging GLP-1 industry revenue exceeded $40B (2024) plus emerging emerging emerging multi-year ramp.
4. Opioid settlement payments. Multi-year emerging opioid settlement payments drives multi-year emerging operator liability. Multi-year emerging McKesson, Cencora, Cardinal Health Big 3 distributors plus emerging emerging Johnson & Johnson plus emerging emerging Walgreens, CVS, Walmart, Kroger settlement plus emerging emerging emerging emerging $26B 2021 master settlement plus emerging emerging emerging emerging emerging state-by-state implementation drive multi-year emerging emerging $1-2B annual settlement payments through 2038.

Major US pharma distribution names

McKesson (MCK)

Largest US pharma distributor plus emerging emerging US Pharmaceutical plus emerging emerging Prescription Technology Solutions plus emerging emerging Medical-Surgical Solutions plus emerging emerging International plus emerging emerging Brian Tyler CEO leadership.

Cencora (COR)

Diversified pharmaceutical distribution plus emerging emerging post-AmerisourceBergen rebrand (August 2023) plus emerging emerging US Healthcare Solutions plus emerging emerging International Healthcare Solutions plus emerging emerging post-Alliance Healthcare integration plus emerging emerging Bob Mauch CEO leadership transition (October 2024).

Cardinal Health (CAH)

Diversified Pharmaceutical & Specialty Solutions plus emerging emerging Global Medical Products & Distribution plus emerging emerging Jason Hollar CEO leadership.

Henry Schein (HSIC)

Diversified dental plus medical-surgical distribution plus emerging emerging dental practice software (see dental supplies decoder) plus emerging emerging Stanley Bergman founder-CEO leadership.

Owens & Minor (OMI)

Diversified medical-surgical distribution plus emerging emerging Patient Direct home delivery (post-Apria Healthcare acquisition 2022) plus emerging emerging Edward Pesicka CEO leadership.

How institutional managers position around pharma distribution

Three patterns appear across smart-money 13Fs:

Pattern 1: Quality-compounder concentration

MCK, COR-concentrated growth manager positions reflect quality pharma distribution oligopoly plus emerging emerging emerging GLP-1 plus emerging specialty pharma growth thesis.

Pattern 2: Turnaround positioning

CAH-concentrated value-discipline manager positions reflect Cardinal Health turnaround plus emerging emerging operational discipline thesis.

Pattern 3: Medical-surgical positioning

HSIC, OMI-concentrated active manager positions reflect medical-surgical distribution plus emerging emerging Patient Direct thesis.

How to read pharma distribution 13F positioning

Three rules apply:

Rule 1: Identify segment exposure

Pharma vs medical-surgical vs dental have distinct dynamics.

Rule 2: Watch organic revenue growth

Multi-year organic revenue drives operator economics.

Rule 3: Cross-check specialty pharma

Multi-year specialty pharma drives operator margin trajectory.

What pharma distribution positioning signals

1. Quality-compounder conviction. Concentrated MCK, COR positions signal quality oligopoly thesis.
2. Turnaround conviction. Concentrated CAH positions signal Cardinal Health turnaround thesis.
3. Medical-surgical conviction. Concentrated HSIC, OMI positions signal medical-surgical thesis.

For real-time tracking of pharma distribution 13F activity, see the institutional signals feed.